首页> 美国卫生研究院文献>other >MicroRNA-7 Inhibits Tumor Metastasis and Reverses Epithelial-Mesenchymal Transition through AKT/ERK1/2 Inactivation by Targeting EGFR in Epithelial Ovarian Cancer
【2h】

MicroRNA-7 Inhibits Tumor Metastasis and Reverses Epithelial-Mesenchymal Transition through AKT/ERK1/2 Inactivation by Targeting EGFR in Epithelial Ovarian Cancer

机译:MicroRNA-7抑制肿瘤转移并通过靶向EGFR在上皮性卵巢癌中通过AKT / ERK1 / 2失活逆转上皮-间质转化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epidermal growth factor receptor (EGFR) overexpression and activation result in increased proliferation and migration of solid tumors including ovarian cancer. In recent years, mounting evidence indicates that EGFR is a direct and functional target of miR-7. In this study, we found that miR-7 expression was significantly downregulated in highly metastatic epithelial ovarian cancer (EOC) cell lines and metastatic tissues, whereas the expression of, EGFR correlated positively with metastasis in both EOC patients and cell lines. Overexpression of miR-7 markedly suppressed the capacities of cell invasion and migration and resulted in morphological changes from a mesenchymal phenotype to an epithelial-like phenotype in EOC. In addition, overexpression of miR-7 upregulated CK-18 and β-catenin expression and downregulated Vimentin expression, accompanied with EGFR inhibition and AKT/ERK1/2 inactivation. Similar to miR-7 transfection, silencing of EGFR with this siRNA in EOC cells also upregulated CK-18 and β-catenin expression and downregulated Vimentin expression, and decreased phosphorylation of both Akt and ERK1/2, confirming that EGFR is a target of miR-7 in reversing EMT. The pharmacological inhibition of PI3K-AKT and ERK1/2 both significantly enhanced CK-18 and β-catenin expression and suppressed vimentin expression, indicating that AKT and ERK1/2 pathways are required for miR-7 mediating EMT. Finally, the expression of miR-7 and EGFR in primary EOC with matched metastasis tissues was explored. It was showed that miR-7 is inversely correlated with EGFR. Taken together, our results suggested that miR-7 inhibited tumor metastasis and reversed EMT through AKT and ERK1/2 pathway inactivation by reducing EGFR expression in EOC cell lines. Thus, miR-7 might be a potential prognostic marker and therapeutic target for ovarian cancer metastasis intervention.
机译:表皮生长因子受体(EGFR)的过度表达和激活导致实体瘤(包括卵巢癌)的增殖和迁移增加。近年来,越来越多的证据表明EGFR是miR-7的直接和功能靶标。在这项研究中,我们发现在高度转移的上皮性卵巢癌(EOC)细胞系和转移组织中,miR-7表达显着下调,而EGFR的表达与EOC患者和细胞系中的转移均呈正相关。 miR-7的过表达显着抑制了细胞侵袭和迁移的能力,并导致EOC中从间充质表型变为上皮样表型的形态变化。此外,miR-7的过表达上调了CK-18和β-catenin的表达,并下调了波形蛋白的表达,并伴有EGFR抑制和AKT / ERK1 / 2失活。与miR-7转染类似,在EOC细胞中用此siRNA沉默EGFR还可上调CK-18和β-catenin表达,并下调Vimentin表达,并降低Akt和ERK1 / 2的磷酸化,证实EGFR是miR的靶标-7在反向EMT中。 PI3K-AKT和ERK1 / 2的药理抑制作用均显着增强了CK-18和β-catenin的表达,并抑制了波形蛋白的表达,表明AKT和ERK1 / 2途径是miR-7介导EMT所必需的。最后,探讨了miR-7和EGFR在原发性EOC转移组织中的表达。结果表明,miR-7与EGFR呈负相关。两者合计,我们的结果表明,miR-7通过减少EOC细胞系中的EGFR表达,通过AKT和ERK1 / 2途径失活抑制肿瘤转移并逆转EMT。因此,miR-7可能是卵巢癌转移干预的潜在预后标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号